The vasodilatory effects of levosimendan on the human internal mammary artery

Anesthesia and Analgesia

Volumn 103, Issue 5, 2006, Pages 1094-1098

  Montes, Félix R ^a,b   Echeverri, Darío ^a   Buitrago, Lorena ^a   Ramírez, Isabel ^a   Giraldo, Juan C ^a   Maldonado, Javier D ^a   Umaña, Juan P ^a  

^a UNIVERSIDAD DE LOS ANDES   (Colombia)

^b TRANEXCO 1194tp6co ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; GLYCERYL TRINITRATE; LEVOSIMENDAN; MILRINONE; NORADRENALIN;

ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VASODILATATION; VASOSPASM;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDRAZONES; MAMMARY ARTERIES; PYRIDAZINES; VASODILATION; VASODILATOR AGENTS;

EID: 33750359693     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000244326.38206.a0     Document Type: Article

References (25)

1. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001;61:613-29.
2. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
3. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensiter, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
4. Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levsimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-28.
5. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of internal mammary artery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1-6.
6. Sarabu MR, McClung JA, Fass A, Reed GE. Early postoperative spasm in left internal mammary artery bypass grafts. Ann Thorac Surg 1987;44:199-200.
7. He G-W, Yang C-Q, Starr A. Overview of the nature of vasoconstriction in arterial grafts for coronary operations. Ann Thorac Surgery 1995;59:676-83.
8. Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42:43-51.
9. Tanaka KA, Szlam F, Katori N, et al. In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery. Br J Anaesth 2004;93:257-62.
10. Huraux C, Makita T, Montes F, et al. A comparative evaluation of the effects of multiple vasodilators on human internal mammary artery. Anesthesiology 1998;88:1654-9.
11. Ignarro LJ. Nitric oxide as unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-14.
12. Hashimoto S, Kobayashi A. Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites. Clin Pharmacokinet 2003;42:205-21.
13. Liu JJ, Doolan LA, Xie B, et al. Direct vasodilator effect of milrinone, an inotropic drug, on arterial coronary bypass grafts. J Thorac Cardiovasc Surg 1997;113:108-13.
14. Bailey JM, Levy JH, Kikura M, et al. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology 1994;81:616-22.
15. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
16. Felker GM, Benza RL, Chandler AB, et al; for OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.
17. Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-17.
18. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002;94:1427-33.
19. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
20. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5-11.
21. Rosenfeldt FL, He G-W, Buxton BF, Angus JA. Pharmacology of coronary artery bypass grafts. Ann Thorac Surg 1999;67:878-88.
22. 2: an endothelium-derived vasoconstrictor in human internal mammary arteries. Ann Thorac Surg 1993;56:97-100.
23. He GW, Rosenfeldt FL, Buxton BF, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation 1989;80:I141-I150.
24. Chardigny C, Jevara VA, Acar C, et al. Vasoreactivity of the radial artery. Comparison with the internal mammary and gastroepiploic arteries with implications for coronary artery surgery. Circulation 1993;88:II115-II127.
25. Hamilton CA, Williams R, Pathi V, et al. Pharmacological characterization of endothelium dependent relaxation in human radial artery: comparison with internal thoracic artery. Cardiovasc Res 1999;42:214-23.